Intellia Therapeutics, Inc. (NTLA) Financials

NTLA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 758.8 million 137.8 million
Dec. 31, 2025 842.1 million 170.7 million
Sept. 30, 2025 925.3 million 176.9 million
June 30, 2025 898.9 million 183.6 million

NTLA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -117.4 million 13.5 million
Dec. 31, 2025 -69.4 million 90.8 million
Sept. 30, 2025 -76.9 million 19.6 million
June 30, 2025 -99.9 million 22.0 million

NTLA Net Income

No data available :(

NTLA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 376.0 million 61.4 million -
Dec. 31, 2025 449.9 million 66.8 million 93.3 million
Sept. 30, 2025 511.0 million - 98.0 million
June 30, 2025 459.7 million - 102.6 million

NTLA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 118.5 million
Dec. 31, 2025 108.4 million
Sept. 30, 2025 110.2 million
June 30, 2025 103.7 million

NTLA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 79000 80.7 million 34.8 million -
Dec. 31, 2025 126000 88.7 million 33.1 million -
Sept. 30, 2025 29000 94.7 million 46.3 million 15.8 million
June 30, 2025 239000 97.0 million 27.2 million -

NTLA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 15.0 million 2.2 million
Dec. 31, 2025 23.0 million 6.0 million
Sept. 30, 2025 13.8 million 78.9 million
June 30, 2025 14.2 million -

NTLA

Price: $10.73

52 week price:
7.95
28.25

Earnings Per Share: -3.52 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.1 million

Ebitda: -15.1 million

Market Capitalization: 2.0 billion

Links: